1. Failure of colchicine to reduce inhaled triamcinolone dose in patients with asthma☆☆☆★
- Author
-
Andrea Buchmeier, Phillip Corsello, Karen B. Schmaling, Harold S. Nelson, Kenneth B. Newman, and Ulysses G. Mason
- Subjects
Adult ,Male ,medicine.medical_specialty ,Triamcinolone acetonide ,medicine.drug_class ,Immunology ,Familial Mediterranean fever ,Triamcinolone ,Severity of Illness Index ,Drug Administration Schedule ,Gout Suppressants ,chemistry.chemical_compound ,medicine ,Humans ,Immunology and Allergy ,Colchicine ,Urticarial vasculitis ,Glucocorticoids ,Transaminases ,Aged ,Asthma ,Platelet Count ,business.industry ,Interstitial lung disease ,Adrenergic beta-Agonists ,Immunoglobulin E ,Middle Aged ,medicine.disease ,Dermatology ,Blood Cell Count ,Respiratory Function Tests ,Gout ,chemistry ,Anesthesia ,Corticosteroid ,Female ,business ,medicine.drug - Abstract
In recent years there has been significant interest in alternative antiinflammatory agents in the treatment of asthma. However, many of these medications are limited by modest efficacy, toxicity, or cost. Colchicine is an inexpensive and safe medication, which has unique antiinflammatory properties. Although traditionally used to treat gout, it has also been used in various inflammatory disorders such as familial Mediterranean fever] Behcet's syndrome, urticarial vasculitis, 2 and interstitial lung disease. 3 Prior studies have suggested a potential role for colchicine in the treatment of asthma. 4-7
- Published
- 1997